Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Open-Label, Single Arm and Flexible Dose Study of the Effectiveness and Safety of Oral Use Lurasidone HCl Tablet (LATUDA®) for 40-160 mg/Day in Subjects With Schizophrenia

NCT03393026 is registered in ClinicalTrials.gov with Standard Chem. & Pharm. Co., Ltd. as lead sponsor.

NCT NCT03393026
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03393026 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Open-Label, Single Arm and Flexible Dose Study of the Effectiveness and Safety of Oral Use Lurasidone HCl Tablet (LATUDA®) for 40-160 mg/Day in Subjects With Schizophrenia
Lead sponsor
Standard Chem. & Pharm. Co., Ltd.
Phase
Phase 4
Overall status
Completed
Start date
January 3, 2018
Completion date
September 17, 2019
Enrollment
54 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia